AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

IMMUTEP LIMITED Capital/Financing Update 2008

Feb 14, 2008

65122_rns_2008-02-14_893460ba-6d8d-4519-a679-d3758f9c8c69.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

==> picture [193 x 52] intentionally omitted <==

ASX ANNOUNCEMENT

DISPATCH OF REPLACEMENT PROSPECTUS

Non-Renounceable Rights Issue of Options Pro rata offer of 1 option for each 3 shares held at the record date.

Friday 15[th] February 2008, Sydney, Australia: Prima Biomed Limited (ASX: PRR) confirms the pro rata rights offer replacement prospectus was dispatched to shareholders yesterday.

For further information:

Company Enquiries Ata Gokyildirim 0408 685 548

About Prima Biomed Ltd

Prima Biomed (ASX: PRR) is a biotechnology company based in Sydney, Australia. The Company is focused on technologies in the fields of immunology and cancer immunotherapy. Prima is focused on developing a dendritic-cell based immunotherapy targeting mucin-1 tumour expressed antigen. Prima’s lead product, CVac™ has completed Phase IIa clinical development in Ovarian Cancer.

Prima BioMed Ltd , Suite 1705, 109 Pitt St, Sydney NSW 2000 AUSTRALIA Ph: (02) 9232 4420 www.primabiomed.com.au ABN 90 009 237 889